Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
After finishing at $1.21 in the prior trading day, Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) closed at $1.16, down -4.13%. In other words, the price has decreased by -$4.13 from its previous closing price. On the day, 1.79 million shares were traded. LXRX stock price reached its highest trading level at $1.21 during the session, while it also had its lowest trading level at $1.14.
Ratios:
Our goal is to gain a better understanding of LXRX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.16 and its Current Ratio is at 4.16. In the meantime, Its Debt-to-Equity ratio is 0.47 whereas as Long-Term Debt/Eq ratio is at 0.47.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on March 05, 2025, Downgraded its rating to Market Perform and sets its target price to $1 from $2 previously.
On June 17, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $10.
On April 30, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $5.Leerink Partners initiated its Outperform rating on April 30, 2024, with a $5 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LXRX now has a Market Capitalization of 421542848 and an Enterprise Value of 362121632. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.21 while its Price-to-Book (P/B) ratio in mrq is 3.26. Its current Enterprise Value per Revenue stands at 6.197 whereas that against EBITDA is -3.433.
Stock Price History:
The Beta on a monthly basis for LXRX is 1.28, which has changed by -0.39267015 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, LXRX has reached a high of $2.17, while it has fallen to a 52-week low of $0.28. The 50-Day Moving Average of the stock is 15.58%, while the 200-Day Moving Average is calculated to be 47.86%.
Shares Statistics:
The stock has traded on average 3.96M shares per day over the past 3-months and 2917410 shares per day over the last 10 days, according to various share statistics. A total of 363.40M shares are outstanding, with a floating share count of 182.59M. Insiders hold about 49.76% of the company’s shares, while institutions hold 23.87% stake in the company. Shares short for LXRX as of 1753920000 were 27056081 with a Short Ratio of 6.83, compared to 1751241600 on 33206588. Therefore, it implies a Short% of Shares Outstanding of 27056081 and a Short% of Float of 20.79.
Earnings Estimates
The dynamic stock of Lexicon Pharmaceuticals Inc (LXRX) is currently attracting attention from 4.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.06, with high estimates of -$0.05 and low estimates of -$0.08.
Analysts are recommending an EPS of between -$0.16 and -$0.22 for the fiscal current year, implying an average EPS of -$0.19. EPS for the following year is -$0.29, with 5.0 analysts recommending between -$0.19 and -$0.36.
Revenue Estimates
4 analysts predict $5.81M in revenue for the current quarter. It ranges from a high estimate of $10.3M to a low estimate of $1.27M. As of the current estimate, Lexicon Pharmaceuticals Inc’s year-ago sales were $1.75MFor the next quarter, 4 analysts are estimating revenue of $7.56M. There is a high estimate of $10.7M for the next quarter, whereas the lowest estimate is $1.89M.
A total of 4 analysts have provided revenue estimates for LXRX’s current fiscal year. The highest revenue estimate was $51.1M, while the lowest revenue estimate was $32.66M, resulting in an average revenue estimate of $41.92M. In the same quarter a year ago, actual revenue was $31.08MBased on 5 analysts’ estimates, the company’s revenue will be $12.25M in the next fiscal year. The high estimate is $27.5M and the low estimate is $6.02M.
